Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

PRQR holding history

ProQR Therapeutics N.V. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

PRQR overviewAll 13F holders of PRQRFull Q2 2026 holdings

Shares (Q2 2026)
639,243
Value
$1.19M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of PRQR by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026639,243$1.19M<0.1%+333,979+109.4%AddedHolders
Q1 2026305,264$494.5K<0.1%−492,400−61.7%ReducedHolders
Q4 2025797,664$1.61M<0.1%+703,114+743.6%AddedHolders
Q3 202594,550$201.4K<0.1%−1,049,285−91.7%ReducedHolders
Q2 20251,143,835$2.33M<0.1%−643,214−36.0%ReducedHolders
Q1 20251,787,049$2.38M<0.1%−523,001−22.6%ReducedHolders
Q4 20242,310,050$6.12M<0.1%+2,307,150+79,556.9%AddedHolders
Q3 20242,900$5.28K<0.1%−24,646−89.5%ReducedHolders
Q2 202427,546$45.7K<0.1%+22,576+454.2%AddedHolders
Q1 20244,970$11.4K<0.1%+1,070+27.4%AddedHolders
Q4 20233,900$7.72K<0.1%−6,144−61.2%ReducedHolders
Q3 202310,044$13.1K<0.1%+5,363+114.6%AddedHolders
Q2 20234,681$7.58K<0.1%+1,081+30.0%AddedHolders
Q1 20233,600$7.67K<0.1%+656+22.3%AddedHolders
Q4 20222,944$10.9K<0.1%−2,154−42.3%ReducedHolders
Q3 20225,098$4.00K<0.1%+5,098NewHolders
Q1 20220$00.0%−84,327−100.0%Sold outHolders
Q4 202184,327$675.0K<0.1%−9,789−10.4%ReducedHolders
Q3 202194,116$787.0K<0.1%+32,103+51.8%AddedHolders
Q2 202162,013$418.0K<0.1%−28,602−31.6%ReducedHolders
Q1 202190,615$599.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.